Chairman Philip Hampton, who joined GlaxoSmithKline after its Novartis asset swap upped the ante in consumer health, is now stepping down as the British drugmaker prepares to split up the business.
GlaxoSmithKline said Monday that chairman Philip Hampton plans to step down from his position and the process to find a successor has been initiated. Hampton joined the drugmaker's board at the start of 2015, becoming chairman later that year.